Publications by authors named "G F Cota"
Cutaneous leishmaniasis (CL) is a neglected tropical disease that poses a significant public health challenge in Brazil and worldwide. Miltefosine, the only orally administered drug available for CL, was recently incorporated into Brazil's treatment protocols following recommendations by the World Health Organization (WHO) and revisions by national health authorities. While this represents an important advancement, miltefosine is associated with frequent gastrointestinal side effects and potential teratogenic risks, necessitating careful patient eligibility assessments and close clinical monitoring throughout treatment.
View Article and Find Full Text PDFThis study aimed to estimate the cost-effectiveness of four therapeutic approaches available for mucosal leishmaniasis in Brazil: miltefosine, meglumine antimoniate, combined with and without pentoxifylline, and liposomal amphotericin B. The perspective adopted was that of the Brazilian Unified National Health System (SUS). The outcome of interest was "cured patient", which was analyzed using a decision tree model.
View Article and Find Full Text PDFArticle Synopsis
- Effective treatment for brucellosis in children is under-researched, so this study reviews existing literature to evaluate treatments and highlight research gaps.* -
- The systematic review analyzed 11 studies involving 1,156 children, finding that sulfamethoxazole-trimethoprim combined with rifampicin had low failure rates but very low evidence certainty.* -
- The findings stress the need for more high-quality research to better understand the effectiveness of current treatment regimens for pediatric brucellosis, as adverse effects and recovery times were not well documented.*
Blood transfusion remains an important aspect of patient management in visceral leishmaniasis (VL). However, transfusion triggers considered are poorly understood. This review summarises the transfusion practices adopted in VL efficacy studies using the Infectious Diseases Data Observatory VL clinical trials library.
View Article and Find Full Text PDFVisceral leishmaniasis (VL) is an infectious disease caused by Leishmania infantum. Clinically, VL evolves with systemic impairment, immunosuppression and hyperactivation with hypergammaglobulinemia. Although renal involvement has been recognized, a dearth of understanding about the underlying mechanisms driving acute kidney injury (AKI) in VL remains.
View Article and Find Full Text PDF